Phase 4
Completed N=51
Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty
Source: ClinicalTrials.gov NCT01267279 ↗Enrolled (actual)
51
Serious AEs
9.8%
Results posted
Dec 2018
Primary outcomePrimary: Bone Mineral Density (BMD) — -3.97; 14.30; -27.3; -9.58 Percent change
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
In a randomized, double-blind trial, BMD of the operated proximal femur after total hip replacement measured by dual-energy x-ray absorptiometry (DXA) were compared for up to two years in patients receiving IV ZOL 5 mg infusion (n = 27) or placebo (IV saline infusion; n = 24) at two weeks and one year after surgery.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Bone Mineral Density (BMD) |
-3.97; 14.30; -27.3; -9.58 | — |
Eligibility Criteria
Inclusion Criteria
- Patients undergoing primary elective total hip replacement
Exclusion Criteria
- Osteoporosis (BMD ≤-2.5)
- Trauma to the operated femur, hip revisions, femoral dysplasia, trochanteric osteotomy, inflammatory arthritis
- Severe renal impairment
- Use of any medications affecting BMD
- Known sensitivity to bisphosphonates
- Severe dental problems, and pregnancy or being able to conceive and not using reliable birth control methods
Data sourced from ClinicalTrials.gov (NCT01267279). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.